SAVA News and Press, Cassava Sciences Inc.

2024-07-01 12:19:08 ET Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava. ...

2024-07-01 12:17:48 ET More on Cassava Sciences All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment Cassava Sciences plunges 40% after simufilam researcher indicted on fraud charges Cassava swings to Q1 profit as more patients finish simufilam phase 3 trial...

2024-07-01 07:30:04 ET H.C. Wainwright analyst issues NEUTRAL recommendation for SAVA on July 1, 2024 06:07AM ET. The previous analyst recommendation was Buy. SAVA was trading at $12.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 50.0% to $0.495 on volume of 360,218,139 shares NVIDIA Corporation (NVDA) fell 0.4% to $123.54 on volume of 307,578,749 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) rose 8.1% to $0.3343 on vol...

AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured med...

2024-06-28 13:52:13 ET More on Cassava Sciences All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials Cassava Sciences GAAP EPS of -$0.43 beats by $0.03 Seeking Alpha’...

2024-06-19 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...

2024-06-08 14:00:00 ET More on Eli Lilly, Biogen Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Biogen favored at RBC as Eli Lilly awaits FDA AdCom on Alzheimer’s drug FDA suggests safety warning for Eli Lilly Alzheimer’s drug ...

2024-06-04 05:07:02 ET Summary Cassava Sciences is advancing simufilam, a Phase 3 drug for Alzheimer's, amid scrutiny over data integrity and trial conduct. Despite operational progress, significant concerns about simufilam's efficacy and the validity of clinical data persist. ...